Risks of nonsteroidal antiinflammatory drugs in undiagnosed intensive care unit pneumococcal pneumonia: Younger and more severely affected patients

Journal of Critical Care

Volumn 29, Issue 5, 2014, Pages 733-738

  Messika, Jonathan ^a,b   Sztrymf, Benjamin ^a   Bertrand, Fabrice ^a   Billard Pomares, Typhaine ^a,b   Barnaud, Guilene ^a   Branger, Catherine ^a,b   Dreyfuss, Didier ^a,b   Ricard, Jean Damien ^a,b  

^a HÔPITAL LOUIS MOURIER   (France)

^b UNIVERSITÉ PARIS DIDEROT   (France)

Author keywords

ICU outcome; Nonsteroidal antiinflammatory drug; Pleural effusion; Severe community acquired pneumonia; Streptococcus pneumonia

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CORTICOSTEROID; NONSTEROID ANTIINFLAMMATORY AGENT; OXYGEN; VASOACTIVE AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; CHRONIC DISEASE; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EXPOSURE; FEMALE; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; HUMAN CELL; INTENSIVE CARE UNIT; LENGTH OF STAY; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INVASIVE PROCEDURE; NONHUMAN; OUTCOME ASSESSMENT; PLEURA EFFUSION; PNEUMONIA; RETROSPECTIVE STUDY; RISK ASSESSMENT; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; TERMINAL DISEASE; VERY ELDERLY; YOUNG ADULT; DRUG USE; MORTALITY; NONINVASIVE VENTILATION; PATIENT IDENTIFICATION; ADVERSE EFFECTS; AGE; APACHE; COMMUNITY-ACQUIRED INFECTIONS; COMPLICATION; CONTRAINDICATIONS; HOSPITALIZATION; INAPPROPRIATE PRESCRIBING; ISOLATION AND PURIFICATION; PLEURAL EFFUSION; PNEUMONIA, PNEUMOCOCCAL; PROSPECTIVE STUDY; RISK;

ADULT; AGE FACTORS; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APACHE; COMMUNITY-ACQUIRED INFECTIONS; COMORBIDITY; FEMALE; HOSPITALIZATION; HUMANS; INAPPROPRIATE PRESCRIBING; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; NONINVASIVE VENTILATION; PLEURAL EFFUSION; PNEUMONIA, PNEUMOCOCCAL; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK; STREPTOCOCCUS PNEUMONIAE;

EID: 84906056235     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2014.05.021     Document Type: Article

References (35)

1. World Health Organization Mortality estimates by cause, age, and sex for the year 2008 [cited 2012 20/08/2012]; Available from:. http://www.whoint/healthinfo/global_burden_disease/en/.
2. Simpson J.C., Macfarlane J.T., Watson J., Woodhead M.A. A national confidential enquiry into community acquired pneumonia deaths in young adults in England and Wales. British Thoracic Society Research Committee and Public Health Laboratory Service. Thorax 2000, 55(12):1040-1045.
3. Holm A., Nexoe J., Bistrup L.A., Dale K. Aetiology and prediction of pneumonia in lower respiratory tract infection in primary care. Br J Gen Pract 2007, 57(540):547-554.
4. Melbye H., Straume B., Aasebo U., et al. Diagnosis of pneumonia in adults in general practice. Relative importance of typical symptoms and abnormal chest signs evaluated against a radiographic reference standard. Scand J Prim Health Care 1992, 10(3):226-233.
5. Raherison C., Peray P., Poirier R., et al. Management of lower respiratory tract infections by French general practitioners: the AIR II study. Analyse Infections Respiratoires. Eur Respir J 2002, 19(2):314-319.
6. Leroy S., Marc E., Bavoux F., et al. Hospitalization for severe bacterial infections in children after exposure to NSAIDs: a prospective adverse drug reaction reporting study. Clin Drug Investig 2010, 30(3):179-185.
7. Souyri C., Olivier P., Grolleau S., Lapeyre-Mestre M. Severe necrotizing soft-tissue infections and nonsteroidal anti-inflammatory drugs. Clin Exp Dermatol 2008, 33(3):249-255.
8. Voiriot G., Dury S., Parrot A., Mayaud C., Fartoukh M. Nonsteroidal antiinflammatory drugs may affect the presentation and course of community-acquired pneumonia. Chest 2011, 139(2):387-394.
9. Mandell L.A., Wunderink R.G., Anzueto A., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44(Suppl 2):S27-S72.
10. Lim W.S., van der Eerden M.M., Laing R., et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003, 58(5):377-382.
11. Fine M.J., Auble T.E., Yealy D.M., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997, 336(4):243-250.
12. Fagon J.Y., Chastre J., Novara A., Medioni P., Gibert C. Characterization of intensive care unit patients using a model based on the presence or absence of organ dysfunctions and/or infection: the ODIN model. Intensive Care Med 1993, 19(3):137-144.
13. Le Gall J.R., Lemeshow S., Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993, 270(24):2957-2963.
14. Sellares J., Lopez-Giraldo A., Lucena C., et al. Influence of previous use of inhaled corticoids on the development of pleural effusion in community-acquired pneumonia. Am J Respir Crit Care Med 2013, 187(11):1241-1248.
15. Aronoff D.M., Bloch K.C. Assessing the relationship between the use of nonsteroidal antiinflammatory drugs and necrotizing fasciitis caused by group A streptococcus. Medicine (Baltimore) 2003, 82(4):225-235.
16. Weng T.C., Chen C.C., Toh H.S., Tang H.J. Ibuprofen worsens Streptococcus pyogenes soft tissue infections in mice. J Microbiol Immunol Infect 2011, 44(6):418-423.
17. Restrepo M.I., Mortensen E.M., Anzueto A. Common medications that increase the risk for developing community-acquired pneumonia. Curr Opin Infect Dis 2010, 23(2):145-151.
18. Ruiz M., Ewig S., Marcos M.A., et al. Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. Am J Respir Crit Care Med 1999, 160(2):397-405.
19. Teepe J., Grigoryan L., Verheij T.J. Determinants of community-acquired pneumonia in children and young adults in primary care. Eur Respir J 2010, 35(5):1113-1117.
20. Gracia M., Martinez-Marin C., Huelves L., et al. Pulmonary damage and bacterial load in assessment of the efficacy of simulated human treatment-like amoxicillin (2,000 milligrams) therapy of experimental pneumococcal pneumonia caused by strains for which amoxicillin MICs differ. Antimicrob Agents Chemother 2005, 49(3):996-1001.
21. Parra A., Ponte C., Cenjor C., Martinez-Marin C., Soriano F. Effect of antibiotic treatment delay on therapeutic outcome of experimental acute otitis media caused by Streptococcus pneumoniae strains with different susceptibilities to amoxicillin. Antimicrob Agents Chemother 2004, 48(3):860-866.
22. Tang C.M., Macfarlane J.T. Early management of younger adults dying of community acquired pneumonia. Respir Med 1993, 87(4):289-294.
23. Esposito A.L. Aspirin impairs antibacterial mechanisms in experimental pneumococcal pneumonia. Am Rev Respir Dis 1984, 130(5):857-862.
24. Jacobs E.R., Soulsby M.E., Bone R.C., Wilson F.J., Hiler F.C. Ibuprofen in canine endotoxin shock. J Clin Invest 1982, 70(3):536-541.
25. Ricard J.-D. The high flow nasal oxygen in acute respiratory failure. Minerva Anestesiol 2012, 78:836-841.
26. Lenglet H., Sztrymf B., Leroy C., Brun P., Dreyfuss D., Ricard J.D. Humidified high flow nasal oxygen during respiratory failure in the emergency department: feasibility and efficacy. Respir Care 2012, 57(11):1873-1878.
27. Sztrymf B., Messika J., Mayot T., Lenglet H., Dreyfuss D., Ricard J.D. Impact of high-flow nasal cannula oxygen therapy on intensive care unit patients with acute respiratory failure: a prospective observational study. J Crit Care 2012, 27:324.e9-324.e13.
28. Sztrymf B., Messika J., Bertrand F., et al. Beneficial effects of humidified high flow nasal oxygen in critical care patients: a prospective pilot study. Intensive Care Med 2011, 37(11):1780-1786.
29. Woodhead M., Welch C.A., Harrison D.A., Bellingan G., Ayres J.G. Community-acquired pneumonia on the intensive care unit: secondary analysis of 17,869 cases in the ICNARC Case Mix Programme Database. Crit Care 2006, 10(Suppl 2):S1.
30. Marrie T.J., Shariatzadeh M.R. Community-acquired pneumonia requiring admission to an intensive care unit: a descriptive study. Medicine (Baltimore) 2007, 86(2):103-111.
31. Concato J., Peduzzi P., Holford T.R., Feinstein A.R. Importance of events per independent variable in proportional hazards analysis. I. Background, goals, and general strategy. J Clin Epidemiol 1995, 48(12):1495-1501.
32. Peduzzi P., Concato J., Kemper E., Holford T.R., Feinstein A.R. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996, 49(12):1373-1379.
33. Vittinghoff E., McCulloch C.E. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol 2007, 165(6):710-718.
34. Burgos J., Lujan M., Falco V., et al. The spectrum of pneumococcal empyema in adults in the early 21st century. Clin Infect Dis 2011, 53(3):254-261.
35. Bewick T., Sheppard C., Greenwood S., et al. Serotypes associated with the development of pneumococcal para-pneumonic effusion in adults. Eur Respir J 2013, 42(3):733-741.